Responses to CAR T-cell therapy and survival
| . | Total (N = 87) . | Axi-cel (n = 50) . | Liso-cel (n = 37) . |
|---|---|---|---|
| Median follow-up (95% CI), mo | 11 (10-14) | 12 (10-18) | 10 (9-14) |
| Best response | |||
| CR | 68% (57-77) | 72% (58-84) | 62% (45-78) |
| PR | 21% (13-31) | 20% (10-34) | 22% (10-38) |
| 1-mo response | |||
| CR | 54% (43-65) | 62% (47-75) | 43% (27-61) |
| PR | 28% (19-38) | 26% (15-40) | 30% (16-47) |
| PFS, median (95% CI) | NR (9 to NR) | NR (9 to NR) | 11 (6 to NR) |
| 12-mo PFS | 53%, (42-66) | 59% (45-76) | 44% (29-68) |
| DOR, median (95% CI) | NR (11 to NR) | NR (11 to NR) | NR (9 to NR) |
| 12-mo DOR | 61% (49-76) | 62% (48-81) | 59% (41-86) |
| OS, median (95% CI) | NR (NR to NR) | NR (NR to NR) | NR (NR to NR) |
| 12-mo OS | 74% (64-86) | 77% (65-92) | 71% (55-91) |
| . | Total (N = 87) . | Axi-cel (n = 50) . | Liso-cel (n = 37) . |
|---|---|---|---|
| Median follow-up (95% CI), mo | 11 (10-14) | 12 (10-18) | 10 (9-14) |
| Best response | |||
| CR | 68% (57-77) | 72% (58-84) | 62% (45-78) |
| PR | 21% (13-31) | 20% (10-34) | 22% (10-38) |
| 1-mo response | |||
| CR | 54% (43-65) | 62% (47-75) | 43% (27-61) |
| PR | 28% (19-38) | 26% (15-40) | 30% (16-47) |
| PFS, median (95% CI) | NR (9 to NR) | NR (9 to NR) | 11 (6 to NR) |
| 12-mo PFS | 53%, (42-66) | 59% (45-76) | 44% (29-68) |
| DOR, median (95% CI) | NR (11 to NR) | NR (11 to NR) | NR (9 to NR) |
| 12-mo DOR | 61% (49-76) | 62% (48-81) | 59% (41-86) |
| OS, median (95% CI) | NR (NR to NR) | NR (NR to NR) | NR (NR to NR) |
| 12-mo OS | 74% (64-86) | 77% (65-92) | 71% (55-91) |
Values are presented as rate (95% CI) unless otherwise stated.
NR, not reached.